Leukadherin-1|cas:344897-95-6|西域试剂

Leukadherin-1,98.0%

产品编号：Bellancom-15701| CAS NO：344897-95-6| 分子式：C₂₂H₁₅NO₄S₂| 分子量：421.49

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-15701	￥500.00	杭州北京（现货）
Bellancom-15701	￥800.00	杭州北京（现货）
Bellancom-15701	￥2300.00	杭州北京（现货）
Bellancom-15701	￥4200.00	杭州北京（现货）
Bellancom-15701	￥6400.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Leukadherin-1

产品介绍

Leukadherin-1 是特异性的白细胞表面整合素 CD11b/CD18 的激动剂。Leukadherin-1 可增加 CD11b/CD18 依赖性细胞对血纤蛋白原的粘附，EC₅₀为 4 μM。Leukadherin-1 增强白细胞对配体 (如 ICAM-1) 和血管内皮的粘附，从而减少白细胞跨内皮迁移和流入损伤部位。Leukadherin-1 抑制先天性炎症信号转导。

生物活性

Leukadherin-1, a specific agonist of the leukocyte surface integrin CD11b/CD18, increases CD11b/CD18-dependent cell adhesion to fibrinogen with an EC₅₀ of 4 μM. Leukadherin-1 enhances leukocyte adhesion to ligands (such as ICAM-1) and vascular endothelium and thus reduces leukocyte transendothelial migration and influx to the injury sites. Leukadherin-1 suppresses innate inflammatory signaling.

体外研究

Leukadherin-1 is a specific agonist of the leukocyte surface integrin CD11b/CD18 (αMβ2; CR3; Mac-1). Leukadherin‐1 pretreatment reduces secretion of interferon (IFN)‐γ, tumour necrosis factor (TNF) and macrophage inflammatory protein (MIP)‐1β by monokine‐stimulated NK cells. Leukadherin‐1 pretreatment also reduces secretion of IL‐1β, IL‐6 and TNF by Toll‐like receptor (TLR)‐2 and TLR‐7/8‐stimulated monocytes.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Leukadherin-1 (1 mg/kg; i.p.; twice daily for 14 days) is beneficial in preventing hyperoxia-induced neonatal lung injury, an experimental model of bronchopulmonary dysplasia (BPD).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Newborn Sprague Dawley rat pups
Dosage:	1 mg/kg
Administration:	I.p.; twice daily for 14 days
Result:	Beneficial on preventing the lung inflammatory response, improved alveolarization and vascular development, and reduced pulmonary vascular remodeling and PH in a hyperoxia-induced experimental model of BPD.

体内研究

Leukadherin-1 (1 mg/kg; i.p.; twice daily for 14 days) is beneficial in preventing hyperoxia-induced neonatal lung injury, an experimental model of bronchopulmonary dysplasia (BPD).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Newborn Sprague Dawley rat pups
Dosage:	1 mg/kg
Administration:	I.p.; twice daily for 14 days
Result:	Beneficial on preventing the lung inflammatory response, improved alveolarization and vascular development, and reduced pulmonary vascular remodeling and PH in a hyperoxia-induced experimental model of BPD.

性状

Solid

溶解性数据

In Vitro:

DMSO : 5 mg/mL (11.86 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3725 mL	11.8627 mL	23.7254 mL
5 mM	0.4745 mL	2.3725 mL	4.7451 mL
10 mM	0.2373 mL	1.1863 mL	2.3725 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式